Center of Virology and biotechnology “Vector” together with the company BIOCAD intends to register the vaccine for smallpox virus and begin production in 2021, reports TASS.
“In December 2019 successfully completed the first phase of clinical trials on human volunteers, in September of 2020, we begin the second, the third phase of clinical trials and expect to continue to register and enter production in 2021,” – said General Director of “Vector” at a meeting with Russian President Vladimir Putin on the development of genetic technologies.
Maksyutov noted that this vaccine obtained by genetic engineering, through a consistent threat off the six genes in the original strain.
“According to our ambitious plans, in 2021 we with our industrial partner will provide SUPPLIES for the population of the Russian Federation a unique vaccine against the dangerous virus on the planet, the smallpox virus”, he added.
Earlier the head of Rospotrebnadzor Anna Popova said that despite the eradication of smallpox in 1977, the risk of this disease still exist. “Smallpox eliminated, the population ceased to instill in 1980 against smallpox. This creates a high risk of temptation for the misuse of this pathogen, first- for non-peaceful purposes, and, secondly, in the event of his unexpected appearances. Therefore, vaccine supplies should be,” she said.